PFE · PFIZER INC

489 filings

PFE SEC Filings

PFIZER INC - 489 total filings

Filing record · 2016–202610-K1110-Q328-K146

Showing 1–50 of 489 filings

PFIZER INC 8-K Report, Financial Results (Aug 4, 2026)

Pfizer reported second-quarter 2026 results on August 4, 2026, showing revenues of $15.0 billion, up 3% reported and 1% operationally, with Adjusted diluted EPS of $0.77 (flat year over year). Growth was narrow: excluding Comirnaty and Paxlovid, revenues rose 5% operationally, and products the company classifies as Launched and Acquired grew 18%. Reported results were a loss of $(0.04) per share, driven by $4.3 billion in non-cash intangible asset impairments (chiefly $3.8 billion on sigvotatug vedotin's Phase 3 lung cancer IPR&D asset after unfavorable trial results, and $525 million on Oxbryta) and a $1.9 billion gain from selling the ViiV Healthcare stake, which was offset by higher legal charges. Management raised the midpoint of full-year 2026 revenue guidance by $500 million to $60.5-$62.5 billion, citing about $1.5 billion of better-than-expected non-COVID performance, partly offset by a cut in COVID-19 product revenue expectations to about $4 billion from $5 billion. Adjusted diluted EPS guidance of $2.80-$3.00 was reaffirmed, but it absorbs roughly $0.10 from a $650 million acquired IPR&D charge tied to the Innovent Biologics licensing deal, which closed July 10, 2026 and will be recorded in Q3 2026. The company also expanded its cost programs with about $2.5 billion of additional net savings expected from 2027 through 2029, against roughly $2.0 billion of one-time costs for the cost realignment initiative, and an additional $1.5 billion of COGS savings with about $4.0 billion in one-time costs. Total net savings targets now reach about $6.7 billion (cost realignment) and $3.0 billion (manufacturing optimization). Leadership changes and capital allocation are also in focus. CFO Dave Denton departs August 15, 2026, and Cecile Guegan becomes Interim CFO on August 16 during a search for a permanent successor. Pfizer paid $4.9 billion in dividends ($0.86 per share) in the first half and made no share repurchases in 2026, with $3.3 billion of authorization remaining. Management said it is prioritizing reinvestment and de-leveraging, and the guidance assumes no buybacks.

Aug 4, 2026 10-Q

PFIZER INC Quarterly Report for Q2 Ended Jun 28, 2026

Pfizer Inc. reported mixed financial results for the quarter and six months ended June 28, 2026. Total revenues saw a modest increase of 3% year-over-year to $15.0 billion for the quarter, driven by strong performance in key products like Eliquis and the Vyndaqel family, partially offset by declining COVID-19 product revenues. Operationally, excluding COVID-19 products, total revenues grew by 1% for the quarter and 6% for the year-to-date period. The company reported a net loss of $0.04 per share for the quarter, a significant shift from a net income of $0.51 per share in the prior year, largely due to substantial intangible asset impairment charges and legal expenses. The six-month period also showed a decrease in net income per share to $0.43 from $1.03 in the prior year. Significant factors impacting profitability include substantial intangible asset impairment charges of $4.3 billion, primarily related to IPR&D assets for a non-small cell lung cancer treatment and developed technology rights for Oxbryta, as well as increased research and development expenses and cost of sales. The company also completed the exit of its investment in ViiV, generating $1.875 billion in cash proceeds, which contributed to a notable gain in "Other (income)/deductions—net."

Aug 4, 2026 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Jun 18, 2026)

Pfizer Inc. (PFE) filed an 8-K on June 18, 2026, primarily to reaffirm its previously issued fiscal year 2026 financial guidance following the announcement of a Chief Financial Officer transition. The company reiterated its revenue guidance of $59.5 billion to $62.5 billion and its Adjusted Diluted Earnings Per Share (EPS) guidance of $2.80 to $3.00. This reaffirmation suggests that despite the executive change, Pfizer's management remains confident in the company's operational and financial outlook for the remainder of the fiscal year. Investors should note that this filing does not introduce new financial targets but rather confirms existing ones, providing a degree of stability amidst organizational adjustments. The extensive risk factors included in the filing underscore the inherent volatility and uncertainties associated with the pharmaceutical industry.

Jun 18, 2026 8-K

PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)

Pfizer Inc. (PFE) disclosed in an 8-K filed June 18, 2026 that Chief Financial Officer Dave Denton will step down effective August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company states the departure is not related to its financial or operating results, or to any disagreements over financial, operational, accounting, or reporting policies or practices. This is a leadership transition rather than a change in reported financial performance, and the filing contains no financial results, guidance changes, or quantitative disclosures. Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer from August 16, 2026, while Pfizer conducts a comprehensive internal and external search for a permanent successor. Ms. Guegan, 55, joined Pfizer in 2005 and has held her current role since 2022, with prior finance leadership positions including Vice President, Finance, Research & Development and Business Office from 2020 to 2022. She is directly responsible for the financial operations and reporting of Pfizer's biopharmaceutical business, and she led finance integration of Seagen in 2024. Mr. Denton and Ms. Guegan will work together to ensure a seamless handover, which mitigates near-term execution risk. For investors, the key items to monitor are the timing and profile of the permanent CFO hire, any change in capital allocation or guidance tone under new leadership, and whether the transition affects the integration of recent large transactions the CEO cited, including Seagen, Biohaven, and Metsera. The filing describes the change as orderly and unrelated to accounting or performance concerns, but a CFO vacancy during an ongoing search carries some uncertainty until a permanent appointment is made.

Jun 18, 2026 8-K

PFIZER INC 8-K Report, Financial Results (May 5, 2026)

Pfizer (PFE) reported first-quarter 2026 results on May 5, 2026, with total revenues of $14.5 billion, up 5% reported and 2% operationally. Excluding the steep declines in COVID-19 products Comirnaty and Paxlovid, revenue grew 7% operationally, and revenues from the company's Launched and Acquired Products rose 22%. Reported diluted EPS was $0.47, down 10% year over year, while Adjusted diluted EPS was $0.75, down 18% from $0.92. The earnings decline was driven by higher cost of sales (reflecting the non-recurrence of a prior-year royalty accrual revision), higher R&D spending, a higher effective tax rate, and a sharp drop in Adjusted EPS relative to the prior year, partly offset by lower SI&A expenses. Pfizer reaffirmed all components of its full-year 2026 guidance, including revenues of $59.5 to $62.5 billion and Adjusted diluted EPS of $2.80 to $3.00. Guidance embeds an anticipated approximately $1.5 billion unfavorable revenue impact from generic and biosimilar competition and assumes no share repurchases in 2026. Management highlighted strong growth in Padcev, Eliquis, Nurtec, Lorbrena and oncology biosimilars, and pipeline momentum including positive Phase 3 readouts for Braftovi, Elrexfio and Talzenna, a Phase 2 readout for atirmociclib, and an encouraging Phase 2 result for tilrekimig. The Lyme disease vaccine candidate missed its first pre-specified statistical criterion, a notable setback. Capital allocation remained focused on reinvestment and the dividend: Pfizer invested $2.5 billion in internal R&D, paid $2.4 billion in dividends ($0.43 per share), and completed no share buybacks in the quarter. Additional items of note include the completed exit of its ViiV Healthcare stake for $1.875 billion (about $1.65 billion net cash, to be recognized in Q2 2026), and April settlements extending U.S. Vyndamax patent protection to June 1, 2031, which management says should keep revenues relatively stable through mid-2031 rather than declining from 2029.

May 5, 2026 10-Q

PFIZER INC Quarterly Report for Q1 Ended Mar 29, 2026

Pfizer Inc. reported total revenues of $14.45 billion for the first quarter of 2026, an increase of 5% compared to the prior year, driven by operational growth of 2% and a favorable foreign exchange impact of 3%. While overall revenue showed positive momentum, the company experienced a significant decline in COVID-19 product revenues (Comirnaty and Paxlovid), down 59% and 63% respectively. However, this was largely offset by strong performance in key therapeutic areas, including Eliquis (up 8% operationally), Vyndaqel family (up 4%), Ibrance (down 1% operationally, but with positive demand drivers), and Padcev (up 39%). Profitability saw a mixed picture. Net income attributable to Pfizer Inc. common shareholders was $2.69 billion, a decrease from $2.97 billion in the prior year. This was impacted by a substantial increase in the cost of sales, up 25%, largely due to the non-recurrence of a favorable royalty estimate revision from the prior year and unfavorable foreign exchange. Research and development expenses also increased by 13%, reflecting investments in oncology and obesity candidates. Despite these pressures, the company's strategic cost management initiatives and strong operational execution in key growth areas position it for continued development. The company also announced a significant acquisition of Metsera, a biopharmaceutical company focused on obesity and cardiometabolic diseases, for $8.0 billion.

May 5, 2026 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 27, 2026)

Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor. All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers. However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.

Apr 27, 2026 10-K

PFIZER INC Annual Report, Year Ended Dec 31, 2025

Pfizer Inc.'s 2025 10-K filing reveals a company navigating a dynamic landscape, with total revenues experiencing a slight 2% decrease to $62.6 billion, primarily due to a significant decline in COVID-19 product revenues (Comirnaty and Paxlovid). Excluding these products, the company saw a 6% operational revenue increase, driven by strong performance in its Vyndaqel family, Eliquis, Padcev, and oncology portfolio. The company is strategically focused on maximizing value from key transactions, delivering on R&D milestones, investing for post-2028 growth, and scaling AI across its business. Pfizer continues to manage significant patent expirations, anticipating a substantial reduction in revenue from these events between 2026 and 2030, with an expected impact of $1.5 billion in 2026. The company is also actively managing pricing pressures and regulatory changes, including the impact of the IRA and the U.S. government's Most-Favored-Nation initiatives. Significant investments in business development, such as the acquisitions of Seagen and Metsera, underscore Pfizer's commitment to strengthening its pipeline, particularly in oncology and obesity. Despite revenue headwinds from COVID-19 products and upcoming patent cliffs, Pfizer's diversified portfolio, ongoing R&D investments, and strategic business development initiatives position it to address unmet medical needs and drive future growth. Investors will be closely watching the company's ability to execute on its strategic priorities, manage patent expirations, and adapt to the evolving regulatory and pricing environment.

Feb 26, 2026 8-K

PFIZER INC 8-K Report, Financial Results (Feb 3, 2026)

Pfizer reported fourth-quarter and full-year 2025 results on February 3, 2026, with full-year revenues of $62.6 billion, down 2% reported and operationally, but up 6% operationally excluding Paxlovid and Comirnaty. Full-year reported diluted EPS was $1.36, versus $1.41 in 2024, while adjusted diluted EPS rose 4% to $3.22. Fourth-quarter reported results were a loss of $(0.29) per share, driven largely by $4.4 billion of non-cash intangible asset impairments (including about $3.6 billion of IPR&D, such as $1.6 billion for disitamab vedotin), while adjusted diluted EPS grew 5% to $0.66 and fourth-quarter revenues fell 1% to $17.6 billion. Management reaffirmed 2026 guidance of $59.5 to $62.5 billion in revenues and $2.80 to $3.00 in adjusted diluted EPS. The guidance embeds roughly $5 billion of COVID-19 product revenue, a roughly $1.5 billion headwind from loss of exclusivity, and the anticipated impact of Most-Favored-Nation pricing and TrumpRx. No share repurchases are assumed for 2026, and none were made in 2025, leaving $3.3 billion of authorization remaining. Dividends totaled $9.8 billion, or $1.72 per share, in 2025. The filing highlights a heavy investment phase: $8.8 billion in business development in 2025, mainly the Metsera acquisition and the 3SBio in-license, and about 20 planned key pivotal study starts in 2026. Investors will weigh these pipeline and obesity bets against near-term earnings pressure, the rising impairment charges, and the $1.875 billion cash exit from the ViiV stake expected in Q1 2026.

Feb 3, 2026 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 16, 2025)

On December 16, 2025, Pfizer issued Exhibit 99.1 providing full-year 2026 guidance and revising its full-year 2025 revenue guidance, while reaffirming all other components of its 2025 financial outlook. The company revised 2025 revenue guidance to approximately $62.0 billion, down from the prior $61.0–$64.0 billion range set on November 4, 2025, and reaffirmed 2025 Adjusted diluted EPS of $3.00–$3.15. Pfizer guided 2026 revenues to $59.5–$62.5 billion, with COVID-19 product revenue falling from roughly $6.5 billion to about $5.0 billion and approximately $1.5 billion of negative impact from loss of exclusivity (LOE) products. Management expects roughly 4% operational revenue growth at the midpoint in 2026 excluding COVID-19 and LOE products. The 2026 earnings outlook is weaker than 2025. Adjusted diluted EPS is guided to $2.80–$3.00, versus $3.00–$3.15 for 2025, driven mainly by lower expected revenues and a higher effective tax rate on Adjusted income of about 15%, up from about 11%. Combined 2026 Adjusted SI&A and R&D spending is expected at $23.0–$25.0 billion, reflecting continued cost realignment and increased R&D investment, including the in-licensed PD-1 x VEGF bispecific antibody from 3SBio and Metsera clinical programs. Guidance excludes business development deals not completed as of December 16, 2025, assumes about 5.74 billion diluted shares, and assumes no share repurchases in 2025 or 2026. For investors, the key takeaways are the lower 2025 revenue outlook, a 2026 year that absorbs post-LOE and COVID-related declines, and a step-up in R&D investment that pressures near-term EPS. The filing is furnished under Regulation FD rather than filed, and the forward-looking statements carry substantial risk disclosed in Pfizer's SEC filings.

Dec 16, 2025 8-K

PFIZER INC 8-K Report, Corporate Update (Nov 21, 2025)

Pfizer Inc. (PFE) announced the successful completion of a significant public offering of various debt securities on November 21, 2025. The offering comprised an aggregate principal amount of $6.75 billion across multiple tranches, including Floating Rate Notes due 2027 and fixed-rate notes maturing between 2027 and 2065 with coupon rates ranging from 3.875% to 5.700%. This substantial capital raise was executed under Pfizer's existing shelf registration statement. This offering indicates Pfizer's proactive approach to managing its capital structure and potentially funding ongoing operations, research and development, or strategic initiatives. The diverse maturity dates and interest rate structures of the notes suggest a strategy to diversify its debt profile and optimize borrowing costs. Investors should note the total size of the issuance and the specific terms of each note series to understand Pfizer's current debt obligations and its financial strategy.

Nov 21, 2025 8-K

PFIZER INC 8-K Report, Corporate Update (Nov 13, 2025)

Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. This strategic move signifies Pfizer's expansion into the obesity and metabolic disease market, a key growth area. The acquisition was executed through a merger agreement, with Metsera shareholders receiving $65.60 in cash per share at closing. In addition to the upfront cash payment, Metsera shareholders are eligible to receive contingent value rights (CVRs) worth up to an additional $20.65 per share. These CVRs are tied to the achievement of specific developmental and regulatory milestones related to Metsera's pipeline, notably its GLP-1 receptor antagonist and amylin analog drug candidates. Investors should closely monitor the progress of MET-097i and MET-233i, as their successful advancement could represent significant future value creation for Pfizer.

Nov 13, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Nov 4, 2025)

Pfizer reported third-quarter 2025 results on November 4, 2025 that were mixed on the top line but solid on earnings. Revenues were $16.7 billion, down 6% reported and down 7% operationally, driven by a steep decline in COVID-19 products (Paxlovid down 55% operationally, Comirnaty down 20%). Excluding COVID-19 products, the non-COVID portfolio grew 4% operationally, led by Eliquis (up 22% operationally), Nurtec ODT/Vydura (up 22%), and Vyndaqel family (up 7%). Reported diluted EPS fell 21% to $0.62, reflecting a one-time $1.35 billion acquired IPR&D charge tied to the 3SBio in-licensing deal, while Adjusted diluted EPS was $0.87, down 18% year over year. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised and narrowed Adjusted diluted EPS guidance to $3.00 to $3.15, up from $2.90 to $3.10. The EPS increase was supported by year-to-date performance, cost-reduction progress, and an improved effective tax rate assumption of about 11%, down from 13%. Management also highlighted a landmark agreement with the U.S. government on drug pricing and tariff relief, and early FTC clearance for the pending Metsera acquisition, which has since been contested by a competing Novo Nordisk proposal. For investors, the key tensions are the structural erosion of COVID-19 revenue, the pressure from upcoming generic and biosimilar competition, and the capital allocation trade-off. Pfizer has paid $7.3 billion in dividends, has made no share repurchases in 2025, and is guiding to none. Management is prioritizing de-leveraging while keeping room for business development, including the Metsera deal, which is expected to be financed with cash and new debt.

Nov 4, 2025 10-Q

PFIZER INC Quarterly Report for Q3 Ended Sep 28, 2025

Pfizer Inc. reported a decrease in total revenues for the third quarter of 2025, down 6% to $16.7 billion, primarily due to lower sales of Paxlovid and Comirnaty. This decline was partially offset by growth in key products like Eliquis and the Vyndaqel family. Net income attributable to Pfizer Inc. common shareholders for the quarter was $3.54 billion, a decrease from $4.47 billion in the prior year's third quarter, resulting in diluted EPS of $0.62 compared to $0.78. For the nine-month period ended September 28, 2025, total revenues also saw a slight decrease of 2% to $45.0 billion. Net income attributable to common shareholders increased to $9.42 billion from $7.62 billion in the prior year's nine-month period, with diluted EPS rising to $1.65 from $1.34. The company highlighted significant investments in R&D, including a $1.35 billion charge for an in-licensing agreement with 3SBio. Pfizer is actively managing its cost base through realignment and manufacturing optimization programs, aiming for significant net cost savings. The company also announced a proposed acquisition of Metsera for approximately $4.9 billion, subject to closing conditions.

Nov 4, 2025 10-Q

PFIZER INC Quarterly Report for Q2 Ended Jun 29, 2025

Pfizer Inc. reported strong financial results for the second quarter and first six months of 2025, with total revenues increasing by 10% and 1% respectively, driven by operational growth in key therapeutic areas. Net income attributable to Pfizer Inc. common shareholders surged to $2.91 billion ($0.51 per diluted share) for the quarter and $5.88 billion ($1.03 per diluted share) for the year-to-date period, a significant improvement compared to the prior year. The company's cost-reduction initiatives are demonstrating positive impacts, with Selling, Informational, and Administrative expenses decreasing year-over-year. These results reflect robust performance across its Biopharma segment, with notable contributions from products like the Vyndaqel family, Padcev, Xtandi, and Comirnaty, despite some headwinds from increased manufacturer discounts due to the IRA Medicare Part D Redesign and competitive pressures on certain established products. Pfizer is actively managing its operational efficiency and strategic investments, as evidenced by its ongoing cost realignment and manufacturing optimization programs. The company also made significant business development moves, including an in-licensing agreement for a bispecific antibody targeting PD-1 and VEGF, demonstrating a commitment to expanding its pipeline. The company's financial position remains strong, with substantial cash and equivalents and prudent capital allocation strategies, including dividend payments and share repurchases. While patent expiries and evolving regulatory landscapes, particularly concerning drug pricing, present ongoing challenges, Pfizer's diversified portfolio and strategic investments position it to navigate these complexities.

Aug 5, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Aug 5, 2025)

Pfizer reported second-quarter 2025 results on August 5, 2025, with revenues of $14.7 billion, up 10% on an operational basis, driven by strong growth in Vyndaqel family, Comirnaty, Paxlovid, Padcev, Abrysvo, and Lorbrena, partially offset by Ibrance declines and higher IRA-related Medicare Part D manufacturer discounts. Reported diluted EPS was $0.51 versus $0.01 a year earlier, while Adjusted diluted EPS rose 30% to $0.78. Reported results benefited from net gains on equity securities and lower interest expense, and Pfizer's cost discipline showed through lower SI&A (down 8%) and R&D (down 8%) spending. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised Adjusted diluted EPS guidance by $0.10 at the midpoint to $2.90 to $3.10. The raise absorbs a one-time approximately $0.20 EPS charge from a $1.35 billion acquired IPR&D charge tied to the 3SBio licensing agreement, which will be recorded in Q3 2025. The guidance also reflects a lower assumed effective tax rate of approximately 13% (previously 15%) and reduced SI&A and R&D expense ranges, and it absorbs tariff impacts and potential pricing changes following a July 31, 2025 letter from President Trump. Capital allocation remains focused on de-leveraging and reinvestment. Pfizer paid $4.9 billion in dividends in the first half of 2025 and has made no share repurchases this year, with guidance assuming none for the full year, leaving $3.3 billion of remaining authorization. The company also reiterated its target of approximately $7.2 billion in net cost savings by the end of 2027. Investors should note the Q3 3SBio charge, continued pressure from IRA pricing and generic/biosimilar erosion, and the reliance on COVID-19 products whose demand remains seasonal and uncertain.

Aug 5, 2025 8-K

PFIZER INC 8-K Report, Corporate Update (May 19, 2025)

Pfizer Inc. (PFE) announced through its wholly-owned Dutch subsidiary, Pfizer Netherlands International Finance B.V., the successful completion of a substantial public offering of senior unsecured notes. The offering, totaling €3.25 billion across four tranches with varying maturities and interest rates, was made under a previously established shelf registration statement. This debt issuance represents a strategic move by Pfizer to raise capital, likely for general corporate purposes, potential acquisitions, or to refinance existing debt. The fully and unconditionally guaranteed nature of the notes by Pfizer Inc. provides investors with direct recourse to the parent company, enhancing the security of their investment. Investors should note the specific coupon rates and maturity dates for each tranche of notes, which indicate the cost of borrowing for Pfizer over different time horizons.

May 19, 2025 10-Q

PFIZER INC Quarterly Report for Q1 Ended Mar 30, 2025

Pfizer Inc. reported total revenues of $13.7 billion for the first quarter ended March 30, 2025, a decrease of 8% compared to $14.9 billion in the prior year period. This decline was primarily attributed to a significant drop in Paxlovid sales, which were impacted by lower COVID-19 infections and reduced government purchases, as well as the non-recurrence of a favorable revenue adjustment recognized in the prior year. Despite the overall revenue decrease, operational improvements and growth in key therapeutic areas like the Vyndaqel family, Padcev, and Lorbrena provided some offset. Net income attributable to Pfizer Inc. common shareholders was $2.97 billion, or $0.52 per diluted share, compared to $3.12 billion, or $0.55 per diluted share, in the first quarter of 2024. The decrease in profitability was influenced by lower revenues, increased restructuring charges, and higher intangible asset impairment charges. However, the company is actively managing its cost base through ongoing productivity initiatives and cost realignment programs, which are expected to yield significant savings. Pfizer also completed the sale of its remaining investment in Haleon, generating $6.3 billion in proceeds to support its capital allocation priorities.

May 5, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Apr 29, 2025)

Pfizer reported solid first-quarter 2025 results on April 29, 2025, with revenues of $13.7 billion, down 8% reported (6% operationally) from $14.9 billion a year earlier, largely due to a roughly $1.5 billion decline in Paxlovid. Reported diluted EPS was $0.52 versus $0.55, while Adjusted diluted EPS rose 12% to $0.92 from $0.82, supported by lower SI&A and R&D spending and a low Adjusted tax rate of 7.8%. Pfizer reaffirmed all components of its 2025 guidance, including revenues of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.80 to $3.00, and said it is trending toward the upper end of the EPS range. Guidance excludes any impact from future tariff changes. The more consequential news is the expansion of the cost realignment program. Pfizer now expects total net cost savings of about $5.7 billion through 2027, comprising the previously stated $4.5 billion by end-2025 plus about $1.2 billion of additional SI&A savings, with one-time costs of about $1.6 billion. A separate R&D reorganization is expected to yield about $500 million in savings by end-2026, to be reinvested in the pipeline, at a one-time cost of about $600 million. Investors should weigh these savings against roughly $2.2 billion in total incremental one-time charges, which will weigh on GAAP results over the coming years, and note that the savings are measured against a 2023 baseline and are subject to execution risk. Capital allocation remains focused on the dividend ($2.4 billion paid in the quarter, $0.43 per share) and deleveraging, with gross leverage now below the company's target. No share repurchases have been made in 2025, and guidance assumes none. Pfizer has $3.3 billion remaining on its repurchase authorization and retains flexibility for business development. Pfizer also fully exited its Haleon stake, generating roughly $3.3 billion in March after roughly $3.0 billion in January.

Apr 29, 2025 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 28, 2025)

Pfizer Inc. (PFE) filed an 8-K on April 27, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on April 24, 2025. The primary focus of the filing is the shareholder votes on several key proposals. Importantly, all director nominees presented were elected to the Board of Directors, indicating continued shareholder confidence in the current leadership. Furthermore, shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the fiscal year 2025, a standard procedure that suggests no major concerns regarding the company's auditors.

Apr 28, 2025 10-K

PFIZER INC Annual Report, Year Ended Dec 31, 2024

Pfizer Inc.'s 2024 Form 10-K highlights a year of revenue growth driven by key products like Paxlovid, the Seagen acquisition, and strong performance from the Vyndaqel family and Eliquis, despite a decline in Comirnaty revenues. Total revenues reached $63.6 billion, a 7% increase year-over-year, with operational growth contributing significantly. The company is strategically focused on improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation in 2025. Pfizer continues to navigate a complex regulatory and competitive landscape, including ongoing discussions around drug pricing, patent expirations for key products, and the integration of the Seagen acquisition, which is expected to generate significant synergies. Investors should note the potential impact of upcoming patent expiries between 2026 and 2030 on revenue streams, alongside ongoing efforts to bolster its product pipeline through internal development and strategic business development.

Feb 27, 2025 8-K

PFIZER INC 8-K Report, Financial Results (Feb 4, 2025)

Pfizer reported fourth-quarter and full-year 2024 results on February 4, 2025, with full-year revenues of $63.6 billion, up 7% operationally, and fourth-quarter revenues of $17.8 billion, up 21% operationally. The headline growth is flattered by a one-time $3.5 billion Paxlovid revenue reversal in fourth-quarter 2023, so the cleaner signal is the 12% operational growth in non-COVID products for the full year. Full-year reported diluted EPS was $1.41 and adjusted diluted EPS was $3.11, while fourth-quarter reported EPS was $0.07 and adjusted EPS was $0.63, the latter depressed by $2.9 billion of non-cash intangible asset impairments. Management reaffirmed all components of 2025 guidance: revenues of $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company raised its cost realignment savings target to approximately $4.5 billion by the end of 2025 and expects to earn $1.5 billion of net savings from the first phase of its Manufacturing Optimization Program by 2027. Guidance assumes about $0.6 billion of revenue erosion from generic and biosimilar competition and no share repurchases in 2025, as Pfizer prioritizes deleveraging following the $43.4 billion Seagen acquisition. Capital allocation remains constrained: no buybacks were executed in 2024, dividends totaled $9.5 billion, and internal R&D spending was $10.8 billion. Pfizer expects to de-lever sufficiently by year-end 2025 to shift toward a more balanced capital allocation strategy, which could include business development or renewed buybacks. Recent pipeline news was mixed, with positive Phase 3 results for Braftovi (BREAKWATER) and sasanlimab (CREST), offset by a Phase 3 DMD program discontinuation and impairment charges. Pfizer also sold about 700 million Haleon shares for roughly $3.0 billion in January 2025, reducing its stake from roughly 15% to 7%.

Feb 4, 2025 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 17, 2024)

Pfizer issued its full-year 2025 guidance on December 17, 2024 and reaffirmed its October 29, 2024 guidance for 2024. For 2025 it expects revenue of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.80 to $3.00. Against a 2024 baseline that excludes about $1.2 billion of non-recurring Paxlovid revenue and about $0.30 of non-recurring EPS benefit, management projects roughly flat to 5% operational revenue growth and 10% to 18% operational Adjusted EPS growth. The 2025 revenue outlook already reflects a roughly $1 billion net headwind from Medicare Part D redesign under the Inflation Reduction Act and about $0.6 billion of generic and biosimilar competition. The guidance rests on continued cost discipline. Pfizer says it has achieved its goal of $4.0 billion in net operating expense savings through 2024 under its cost realignment program and expects an additional $500 million in 2025. It projects 2025 Adjusted SI&A plus R&D expenses of $24.0 to $26.0 billion, and it expects initial net savings from the first phase of its Manufacturing Optimization Program in late 2025, aimed at gross margin improvement. Guidance assumes about 5.74 billion diluted shares and no share repurchases in 2024 or 2025, and it excludes any business development deals not completed by December 16, 2024. Investors should note the optical nature of much of the 2025 EPS growth. The 2024 base is flattered by one-time items, and 2025 loses Haleon equity income from Adjusted earnings after Pfizer reduced its Haleon stake in Q4 2024. Adjusted EPS guidance also assumes a higher effective tax rate of about 15%, compared with about 13% in 2024. The release is furnished under Regulation FD rather than filed, and the detailed presentation is available on Pfizer's investor website.

Dec 17, 2024 10-Q

PFIZER INC Quarterly Report for Q3 Ended Sep 29, 2024

Pfizer Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $17.7 billion, a 31% rise compared to the prior year period. This growth was primarily driven by strong performance in Paxlovid, revenues from newly acquired Seagen products, and the Vyndaqel family, which more than offset declines in other areas. The company's net income attributable to Pfizer Inc. common shareholders was $4.465 billion, a substantial improvement from a net loss in the same quarter last year, largely due to increased revenues and a significant decrease in the cost of sales. This strong financial performance reflects a strategic shift towards oncology and growth in key therapeutic areas, alongside successful integration of recent acquisitions. For the first nine months of 2024, total revenues saw a modest increase to $45.9 billion. The company continues to focus on operational efficiency and cost realignment, with significant restructuring programs underway aimed at optimizing costs and improving margins. Despite ongoing investments in research and development and integration costs from acquisitions, Pfizer demonstrated a robust recovery in profitability, with income from continuing operations before taxes showing a substantial increase year-over-year. The company maintains a strong liquidity position, supported by robust operating cash flows and access to credit facilities, positioning it to continue investing in its pipeline and delivering value to shareholders.

Nov 4, 2024 8-K

PFIZER INC 8-K Report, Financial Results (Oct 29, 2024)

Pfizer reported third-quarter 2024 results on October 29, 2024, with revenues of $17.7 billion, up 31% reported and 32% operationally year-over-year, and raised full-year 2024 guidance for both revenue ($61.0 to $64.0 billion, previously $59.5 to $62.5 billion) and Adjusted diluted EPS ($2.75 to $2.95, previously $2.45 to $2.65). The headline growth is flattered by Paxlovid ($2.7 billion, including a one-time $442 million Strategic National Stockpile delivery) and the year-over-year comparison against a $5.6 billion non-cash inventory write-off in Q3 2023. Management emphasized that excluding Paxlovid and Comirnaty, revenues grew 14% operationally, and that legacy Seagen, Vyndaqel, Eliquis, Xtandi and Nurtec were the main contributors, while Xeljanz and Ibrance declined. GAAP Reported diluted EPS was $0.78 for the quarter, compared with a loss of $0.42 a year earlier. Adjusted diluted EPS was $1.06. Reported results benefited from a much lower cost of sales, which fell 43% to 29.7% of revenues, but were offset by a $420 million charge tied to the expected sale of a facility after Pfizer discontinued its Duchenne muscular dystrophy program, along with higher net interest expense from the Seagen financing. Management reiterated a target of at least $5.5 billion in net cost savings from its cost initiatives, including at least $4 billion by year-end 2024. Capital returns were $7.1 billion in dividends for the first nine months, with no share repurchases year-to-date and none assumed in guidance. For investors, the key questions are the sustainability of COVID-product revenue after 2024, the pace of non-COVID growth, and whether the cost program produces the promised margin expansion. The filing also notes the October 2024 sale of Haleon shares for about $3.5 billion, which reduces Pfizer's stake from roughly 23% to 15%, and the voluntary withdrawal of Oxbryta, which reduces sickle cell sales. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Oct 29, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Oct 15, 2024)

Pfizer's 8-K reports the election of Mortimer J. "Tim" Buckley to its Board of Directors, effective immediately, following the Board's election on October 10, 2024. The Board made the appointment after a search that began in May 2024. Mr. Buckley was also named to the Governance & Sustainability Committee and the Audit Committee. Following his appointment, the Board has 14 directors, 13 of whom are independent. The filing contains no financial results, guidance, or material financial events. Mr. Buckley receives an indemnification agreement and compensation under Pfizer's standard non-employee director arrangements. The filing does not disclose the specific compensation amounts. His addition to the Audit Committee is the most notable governance detail for investors, since it adds a director with extensive investment management and financial markets experience to oversight of financial reporting. Mr. Buckley, age 55, previously served as Chairman and CEO of Vanguard from 2018 until his retirement in 2024. Earlier at Vanguard, he was Chief Investment Officer, overseeing internally managed stock, bond, and money market portfolios, and he held other senior roles, including Chief Information Officer. He also chaired the Children's Hospital of Philadelphia board from 2011 to 2017. Overall, this is a routine board refresh with modest direct investment impact, though it strengthens the Board's financial and capital markets expertise.

Oct 15, 2024 10-Q

PFIZER INC Quarterly Report for Q2 Ended Jun 30, 2024

Pfizer Inc. (PFE) reported $13.28 billion in total revenues for the second quarter of 2024, a slight increase of 2% year-over-year, driven by operational growth from legacy Seagen products and continued demand for its Vyndaqel family and Eliquis, partially offset by declines in Comirnaty and Xeljanz. For the first six months of 2024, total revenues were $28.16 billion, down 11% year-over-year, primarily due to significant declines in Comirnaty and Paxlovid sales. The company experienced a net loss attributable to Pfizer Inc. common shareholders of $41 million for the quarter, a stark contrast to the $2.33 billion net income reported in the same period last year. This shift is largely attributable to increased restructuring charges and acquisition-related costs, unfavorable movements in equity securities, and higher net interest expenses. Despite these challenges, Pfizer is actively pursuing cost realignment and manufacturing optimization programs, signaling a focus on improving future profitability and aligning costs with evolving revenue expectations.

Aug 5, 2024 8-K

PFIZER INC 8-K Report, Financial Results (Jul 30, 2024)

Pfizer reported second-quarter 2024 results on July 30, 2024, with revenues of $13.3 billion, up 2% reported and 3% operationally year-over-year. Growth was modest on a headline basis because Comirnaty revenue fell 87% operationally, but excluding Comirnaty and Paxlovid, revenues grew 14% operationally, driven by legacy Seagen oncology products, Vyndaqel, Eliquis, and Nurtec. This was the first year-over-year topline revenue growth since the fourth quarter of 2022, when COVID revenues peaked. Reported GAAP diluted EPS was just $0.01, versus $0.41 a year earlier, reflecting a $1.3 billion one-time restructuring charge for the new Manufacturing Optimization Program, a $1.1 billion swing in other deductions (including net equity securities losses and higher net interest expense), and a 130.2% effective tax rate. Adjusted diluted EPS was $0.60, down 11% from $0.67. Management raised full-year 2024 guidance to revenues of $59.5–62.5 billion (up $1 billion at the midpoint) and Adjusted diluted EPS of $2.45–2.65 (up $0.30 at the midpoint), with the effective tax rate on Adjusted income lowered to about 13% from 15%. For investors, the key takeaways are the underlying strength of the non-COVID portfolio, the roughly $1.5 billion of expected manufacturing savings by 2027 against about $1.7 billion of one-time costs, and continued dividend payments of $4.8 billion in the first half with no share repurchases planned for 2024. Pipeline setbacks included the failed CIFFREO Phase 3 trial of fordadistrogene movaparvovec for Duchenne muscular dystrophy and a $240 million related impairment, while the giroctocogene fitelparvovec hemophilia A Phase 3 study succeeded.

Jul 30, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 26, 2024)

Pfizer (PFE) filed an 8-K on July 26, 2024 disclosing that its Compensation Committee, on July 24, 2024, approved modifications to outstanding 2022 and 2023 Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) for up to approximately 9,000 active employees, including named executive officers Albert Bourla, David M. Denton, Mikael Dolsten, Aamir Malik, Angela Hwang and Douglas M. Lankler. The changes are voluntary: eligible holders may elect to extend TSRU terms by two years (2022 grants settling in February 2029 instead of 2027; 2023 grants in February 2030 instead of 2028), with vesting moved to the fifth anniversary of grant. For PSAs, participants may elect to extend the three-year performance period by two years, with 2022 awards now settling in 2027 instead of 2025 and 2023 awards in 2028 instead of 2026. Management attributes the move to retention concerns after COVID-era grant prices were set at record highs and the stock has since declined. For investors, the key points are the extended vesting and settlement timelines, which defer potential dilution and cash or share settlement of these awards, and the retention rationale, which signals management's concern about talent retention amid share price weakness. The PSA changes also tighten some features: the operating goal range is 0%-200%, the relative TSR modifier is capped at 25 percentage points, and payouts are capped at target if TSR is negative over the period. Death-related settlement terms are also updated, consistent with 2024 grants. The filing does not quantify the accounting charge, incremental expense, or share count impact, so investors should look to the Schedule TO tender offer documents for those details. The program is structured as a tender offer (the Modification Offer) that had not yet commenced at filing, so final terms, participation rates, and financial effects remain to be confirmed. Investors should monitor the Schedule TO filing and any subsequent disclosures on participation levels and associated compensation expense.

Jul 26, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 10, 2024)

Pfizer Inc. (PFE) has announced a significant leadership transition within its Research & Development division. Dr. Mikael Dolsten, the Chief Scientific Officer and President of Pfizer Research & Development, is initiating a search for his successor after a commendable 15-year tenure. This development signals a potential shift in the strategic direction or operational focus of Pfizer's crucial R&D efforts. Dr. Dolsten is expected to remain with the company in his current capacity until a successor is identified and a smooth transition is facilitated, with a commitment to stay through at least February 28, 2025. Investors should closely monitor the selection process for Dr. Dolsten's replacement, as the new appointee will play a vital role in shaping Pfizer's future drug pipeline and innovation strategy. The company's ability to attract top talent for this critical role will be a key indicator of its ongoing commitment to scientific advancement and long-term growth.

Jul 10, 2024 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 1, 2024)

Pfizer Inc. (PFE) filed an 8-K on July 1, 2024 to disclose the election of Cyrus Taraporevala to its Board of Directors, effective immediately. The board elected him on June 27, 2024, and he will join both the Audit Committee and the Compensation Committee. He receives an indemnification agreement and standard non-employee director compensation. The filing is governance-focused and does not disclose any financial results, guidance, or material operational changes. Taraporevala, age 57, brings substantial investment management experience. He was President and CEO of State Street Global Advisors from 2017 until his retirement in 2022, and previously held leadership roles at Fidelity, BNY Mellon, Legg Mason, and Citigroup, as well as a partnership at McKinsey & Company. He also sits on the boards of Shell plc and Bridgepoint Group plc. Chairman and CEO Albert Bourla framed the appointment as adding investment management and financial markets expertise to the board. For investors, the appointment is a routine board refresh with modest direct financial impact. Its relevance lies in the Audit Committee seat, given his finance background, and the Compensation Committee role, which may bear on executive pay oversight. Investors may also note that his other public company board roles could affect his time commitments, though the filing does not raise concerns about this.

Jul 1, 2024 8-K

PFIZER INC 8-K Report, Exit or Disposal Costs (May 22, 2024)

Pfizer Inc. has announced a multi-year program aimed at reducing its cost of goods sold (COGS), a significant initiative for improving operational efficiency and profitability. The first phase of this program, focusing on operational efficiencies, is projected to yield approximately $1.5 billion in savings by the end of 2027, with some benefits anticipated to materialize starting in 2025. This cost-reduction effort will require an estimated $1.7 billion in one-time costs, primarily for severance and implementation expenses. These charges are expected to be recognized in 2024, with the majority of the cash outlays occurring in 2025 and 2026. Investors should note that these figures are estimates and subject to various assumptions, with actual results potentially differing. The company also cautions that future phases or unforeseen events could lead to additional charges.

May 22, 2024 10-Q

PFIZER INC Quarterly Report for Q1 Ended Mar 31, 2024

Pfizer Inc. (PFE) reported its first-quarter 2024 financial results, showing a notable decrease in total revenues to $14.9 billion from $18.5 billion in the prior year period, a 20% decline driven primarily by lower sales of its COVID-19 products, Comirnaty and Paxlovid. Excluding these, total revenues saw an operational increase of 11%, bolstered by the recent acquisition of Seagen, continued growth in the Vyndaqel family and Eliquis, and the launch of Abrysvo for older adults. Net income attributable to Pfizer Inc. common shareholders significantly decreased to $3.1 billion, or $0.55 per diluted share, compared to $5.5 billion, or $0.97 per diluted share, in the first quarter of 2023. The company continues to manage its cost base, announcing a multi-year enterprise-wide cost realignment program expected to yield at least $4 billion in net cost savings by 2024. Integration of the Seagen acquisition, which closed in December 2023, is ongoing and is expected to generate approximately $1 billion in annual cost synergies by 2026. Pfizer also reported a substantial decrease in operating cash flow, alongside strategic actions such as the partial sale of its Haleon investment, generating $3.5 billion in proceeds.

May 8, 2024 8-K

PFIZER INC 8-K Report, Financial Results (May 1, 2024)

Pfizer reported first-quarter 2024 results on May 1, 2024, with revenues of $14.9 billion, down 20% reported and 19% operationally from $18.5 billion a year earlier. The decline was driven by a steep drop in COVID-19 products: Comirnaty revenues fell 88% operationally to $354 million and Paxlovid fell 50% to $2.0 billion. Excluding those two products, revenues grew 11% operationally to $12.5 billion, supported by legacy Seagen contributions ($742 million), Vyndaqel family growth (up 66%), Eliquis (up 10%), Abrysvo, and Prevnar family (up 7%). Reported diluted EPS was $0.55 (down 44%), and Adjusted diluted EPS was $0.82 (down 33%). Both figures include a $0.11 favorable one-time impact from a $771 million Paxlovid revenue reversal adjustment. Management reaffirmed full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised Adjusted diluted EPS guidance to $2.15 to $2.35, up from $2.05 to $2.25. The company remains on track for at least $4 billion in net cost savings by year-end 2024 under its cost realignment program. Guidance assumes roughly 90% of Comirnaty sales occur in the second half, largely in the fourth quarter, reflecting COVID vaccine seasonality. Capital returned to shareholders included $2.4 billion in dividends ($0.42 per share), with no share repurchases made in 2024 to date and none anticipated under current guidance. For investors, the key takeaways are the strength of the non-COVID portfolio and the margin benefit from lower COVID product mix, offset by higher net interest expense following the Seagen acquisition and a sharp decline in total reported revenue. The quarter's reported GAAP results were weighed down by amortization, interest costs, and legal and Haleon-related items, so Adjusted measures paint a more favorable picture than GAAP figures.

May 1, 2024 8-K

PFIZER INC 8-K Report, Shareholder Vote Results (Apr 29, 2024)

Pfizer Inc. (PFE) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2024. The report primarily focuses on shareholder voting results for various proposals, including the election of directors, ratification of its independent auditor, and advisory votes on executive compensation. All incumbent director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and governance. The selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 also received substantial approval. Furthermore, shareholders voted in favor of the Amended and Restated Pfizer Inc. 2019 Stock Plan and approved, on an advisory basis, the compensation of the company's Named Executive Officers, signaling general agreement with the company's incentive structures and remuneration policies.

Apr 29, 2024 10-K

PFIZER INC Annual Report, Year Ended Dec 31, 2023

Pfizer Inc.'s 2023 Form 10-K filing reveals a significant revenue decline, primarily driven by the substantial decrease in sales of its COVID-19 related products, Comirnaty and Paxlovid. Despite this, the company completed the transformative acquisition of Seagen, significantly bolstering its oncology portfolio with the addition of four in-line medicines and a promising pipeline. Looking ahead, Pfizer is focusing on strategic priorities including achieving oncology leadership, advancing its pipeline for future growth, maximizing the performance of its newer products, and optimizing its cost structure. The company is navigating a dynamic market influenced by increasing pricing pressures, the ongoing patent expirations of key products, and evolving regulatory landscapes globally, including the impact of the Inflation Reduction Act (IRA) in the U.S. Pfizer's robust R&D efforts and strategic business development activities are key to its long-term value creation strategy.

Feb 22, 2024 8-K

PFIZER INC 8-K Report, Financial Results (Jan 30, 2024)

Pfizer reported fourth-quarter and full-year 2023 results on January 30, 2024, showing sharp year-over-year declines driven by the expected fall in COVID-19 revenues. Full-year 2023 revenues were $58.5 billion, down 42% reported (41% operationally), while revenues excluding Comirnaty and Paxlovid grew 7% operationally. Reported diluted EPS was $0.37, down 93%, and Adjusted diluted EPS was $1.84, down 72%. Results were heavily affected by one-time items: $5.6 billion of COVID product inventory write-offs in Q3 2023 and a $3.5 billion non-cash Paxlovid revenue reversal in Q4 2023, which together reduced EPS by $1.36 for the full year. Fourth-quarter Reported diluted EPS was a loss of $(0.60), with Adjusted diluted EPS of $0.10. The quarter also featured the completion of the $43 billion Seagen acquisition in December 2023, which Pfizer positions as the foundation of a new world-class oncology business. Management highlighted a record nine new molecular entity approvals from the FDA in 2023 and strong growth from newer and in-line products such as Abrysvo, Vyndaqel family, and Eliquis. Pfizer reaffirmed its 2024 guidance of $58.5 to $61.5 billion in revenue and Adjusted diluted EPS of $2.05 to $2.25. That EPS range includes a roughly $0.40 dilution from Seagen, mainly financing costs, and assumes no share repurchases. For investors, the key questions are whether non-COVID growth (targeted at 8% to 10% operationally in 2024 including Seagen) can offset the continued COVID revenue decline, whether the cost realignment program delivers at least $4 billion in net savings by end-2024, and how the company manages its increased debt load after the Seagen financing. The dividend was $1.64 per share for 2023, and the company has $3.3 billion remaining on its repurchase authorization but does not plan to use it in 2024.

Jan 30, 2024 8-K

PFIZER INC 8-K Report, Corporate Update (Jan 10, 2024)

Pfizer (PFE) disclosed in this 8-K, filed with a press release dated January 10, 2024, that it received notice of an unsolicited "mini-tender" offer from TRC Capital Investment Corporation to buy up to 4,000,000 shares of common stock at $27.35 per share in cash. The offer price is about 4.4% below the $28.61 closing price on December 27, 2023, the business day before the offer date. The targeted shares represent roughly 0.071% of shares outstanding, so the financial exposure to Pfizer and its shareholders is minimal and the filing contains no operational, financial-performance, or guidance information. Pfizer states it does not endorse the offer and recommends that shareholders not tender. It also states it is not affiliated with TRC Capital, its offer, or its offer documents. The company's position is that the below-market price and numerous conditions make the offer unattractive. Shareholders who have already tendered may withdraw their shares at any time before expiration. The offer is scheduled to expire at 12:01 a.m. New York City time on January 30, 2024, though TRC Capital may extend it at its discretion. For investors, the practical takeaway is that this is a routine, low-materiality disclosure. The main risk is to uninformed holders who might tender shares at a discount to market, since mini-tender offers are exempt from many SEC protections that apply to larger tender offers. Pfizer urges shareholders to check current market quotations and consult a broker or financial advisor before responding to any such offer.

Jan 10, 2024 8-K

PFIZER INC 8-K/A Report, Acquisition Completed (Dec 14, 2023)

On December 14, 2023, Pfizer completed its acquisition of Seagen Inc. through a merger in which Merger Sub was merged into Seagen, leaving Seagen as a wholly owned Pfizer subsidiary. Each Seagen share was converted into the right to receive $229.00 in cash, and Pfizer described the deal as a total enterprise value of approximately $43 billion. Seagen's outstanding equity awards were either cashed out at the merger consideration, based on achievement of applicable performance metrics, or converted into Pfizer cash-based awards on substantially the same terms. Strategically, the deal significantly expands Pfizer's oncology franchise. Seagen contributes a leading antibody-drug conjugate (ADC) platform and four marketed medicines: ADCETRIS, PADCEV, TIVDAK and TUKYSA. Pfizer says its oncology portfolio now includes more than 25 approved medicines and biosimilars across more than 40 indications, and that its oncology pipeline has roughly doubled to 60 programs. Management characterized oncology as a likely significant growth driver that will contribute meaningfully to Pfizer's near- and long-term financial goals. The filing does not quantify revenue contribution, earnings impact, synergies, or the financing used. To address U.S. Federal Trade Commission concerns, Pfizer irrevocably donated the U.S. royalty rights on Bavencio (avelumab) sales to the American Association for Cancer Research. The filing also notes that this document is Amendment No. 1 on Form 8-K/A, filed solely to correct the EDGAR submission header, which had referred to Item 2.02 instead of Item 2.01. The disclosures themselves are unchanged from the original report.

Dec 14, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Dec 14, 2023)

On December 14, 2023, Pfizer completed its acquisition of Seagen Inc. under the Merger Agreement dated March 12, 2023. Seagen became a wholly owned subsidiary of Pfizer, and each Seagen share was converted into the right to receive $229.00 in cash, with equity awards either settled at the same price (adjusted for performance metrics and tax withholding) or converted into Pfizer cash-based awards on substantially similar terms. Pfizer described the transaction as a total enterprise value of approximately $43 billion, one of the largest investments in the company's history, and a major push into oncology. Strategically, the deal gives Pfizer Seagen's antibody-drug conjugate (ADC) platform and four in-line medicines: ADCETRIS, PADCEV, TIVDAK and TUKYSA. Pfizer says its oncology portfolio now includes over 25 approved medicines and biosimilars across more than 40 indications, with nine medicines that are blockbusters or have blockbuster potential, and that its oncology pipeline has roughly doubled to 60 programs. Management expects oncology to become a significant growth driver and a meaningful contributor to its near- and long-term financial goals. A regulatory condition also applies. To address Federal Trade Commission concerns, Pfizer irrevocably donated the U.S. royalty rights to sales of Bavencio (avelumab) to the American Association for Cancer Research. Investors should weigh the large purchase price and integration risk against the expected growth from the ADC franchise. The filing and press release note risks including failure to realize anticipated benefits, integration difficulties, unknown liabilities, and uncertainty around commercial success and pipeline outcomes.

Dec 14, 2023 8-K

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 13, 2023)

Pfizer issued full-year 2024 guidance on December 13, 2023, furnished under Item 7.01 (Regulation FD) as Exhibit 99.1. The company guides to 2024 revenues of $58.5 to $61.5 billion, which includes roughly $3.1 billion from the Seagen acquisition, about $1 billion from reclassifying royalty income into revenue, and approximately $8 billion from Comirnaty and Paxlovid. Excluding COVID products and Seagen, operational revenue growth is guided at 3% to 5%; including Seagen but excluding COVID products, growth is 8% to 10%. Adjusted diluted EPS guidance is $2.05 to $2.25, down from the 2023 guidance range of $1.45 to $1.65 shown in the table. That figure is not a like-for-like decline: the legacy Pfizer 2024 range is $2.45 to $2.65, and the Seagen transaction carries a $0.40 dilutive impact, mainly from financing costs. Adjusted SI&A plus R&D expenses are expected to be $24.8 to $26.8 billion, and the cost realignment program now targets at least $4.0 billion in annual net savings, $500 million more than previously expected. For investors, the key takeaways are that Seagen's contribution and the cost program are central to 2024 earnings, while the reported EPS decline and the dependence on COVID franchises (Comirnaty and Paxlovid) are the main risks. The guidance assumes about 5.75 billion diluted shares, no share repurchases, and mid-November 2023 exchange rates. The company also said Seagen regulatory approvals were received and closing was expected on December 14, 2023.

Dec 13, 2023 8-K

PFIZER INC 8-K Report, Executive Changes (Dec 12, 2023)

Pfizer announced on December 12, 2023 that the HSR waiting period for its acquisition of Seagen expired on December 11, 2023, and that all required regulatory approvals are now in hand. Pfizer now expects to close the roughly pending Seagen merger on December 14, 2023, subject to other customary closing conditions. To address FTC concerns, Pfizer will irrevocably donate U.S. royalty rights on Bavencio (avelumab) to the American Association for Cancer Research, a move that removes a potential regulatory obstacle without, per the filing, a disclosed material financial impact. Alongside the closing, Pfizer is reorganizing its commercial operations effective January 1, 2024. A new Pfizer Oncology Division, combining oncology commercial and R&D operations from Pfizer and Seagen, will be led by Dr. Chris Boshoff as Chief Oncology Officer. Non-oncology commercial operations will be split into a Pfizer U.S. Commercial Division (led by Aamir Malik) and a Pfizer International Commercial Division (led by Alexandre de Germay, who is joining from outside Pfizer). The role of Chief Commercial Officer held by Angela Hwang is being eliminated, effective December 15, 2023. She will receive severance under the Executive Severance Plan, plus retirement-related benefits, and will serve as an advisor to the CEO during the transition. For investors, the key near-term items are deal closing timing, the leadership restructuring that accompanies the integration, and the company's full-year 2024 financial guidance, which management will provide on a call on December 13, 2023. The filing itself does not quantify the financial impact of the reorganization or the Hwang severance. Forward-looking risks flagged include the possibility of failing to realize expected deal benefits, integration difficulties, transaction costs, and the potential for unexpected costs from reorganization.

Dec 12, 2023 10-Q

PFIZER INC Quarterly Report for Q3 Ended Oct 1, 2023

Pfizer Inc. reported a net loss of $2.382 billion ($0.42 per share) for the third quarter of 2023, a significant shift from the $8.608 billion net income ($1.54 per share) in the same period last year. This decline was primarily driven by a substantial decrease in revenues, largely due to lower sales of its COVID-19 products, Comirnaty and Paxlovid. While non-COVID-19 product revenues saw growth, it was not enough to offset the decline from the pandemic-era blockbusters. The company is undertaking a cost realignment program expected to deliver at least $3.5 billion in annual net cost savings, aiming to better align expenses with future revenue expectations. This program, along with ongoing restructuring efforts, reflects Pfizer's strategic focus on adapting to a post-pandemic market and investing in its future growth drivers, including the proposed acquisition of Seagen. Investors will be closely watching the successful integration of Seagen and the performance of its non-COVID-19 portfolio.

Nov 8, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Oct 31, 2023)

Pfizer reported third-quarter 2023 revenue of $13.2 billion, down 42% from the prior-year quarter, as expected declines in COVID-19 products (Paxlovid down 97% and Comirnaty down 70% operationally) drove a 41% operational decline. Excluding those two products, company revenue grew 10% operationally, led by Abrysvo, Vyndaqel family, Prevnar family, and the recently acquired Nurtec ODT/Vydura and Oxbryta. Reported diluted loss per share was $(0.42) and adjusted diluted loss per share was $(0.17), both hit by a $5.6 billion non-cash inventory write-off and other charges that reduced EPS by $0.84. Reported net loss was $(2.4) billion versus net income of $8.6 billion a year earlier. Pfizer reaffirmed full-year 2023 guidance of $58.0 to $61.0 billion in revenue and $1.45 to $1.65 in adjusted diluted EPS. The company also reaffirmed its 6% to 8% non-COVID operational revenue growth target. Guidance continues to include a one-time non-cash revenue reversal of about $4.2 billion tied to the expected return of 7.9 million EUA-labeled Paxlovid treatment courses to the U.S. government, plus the $5.6 billion charge. Management expects the company's cost realignment program, targeting at least $3.5 billion in annual net savings by 2024, to improve operating margins. For investors, the key issues are the sharp drop in COVID-19 revenue, the earnings impact of one-time charges, and whether the non-COVID portfolio and cost savings can offset the decline. Pfizer also continues to pursue its proposed Seagen acquisition, which received unconditional EC antitrust clearance during the quarter. The company did not repurchase shares in 2023 and does not anticipate doing so in its guidance.

Oct 31, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Oct 13, 2023)

Pfizer's October 13, 2023 8-K reports a sharp reset of 2023 guidance driven by COVID products. Full-year 2023 revenue guidance falls to $58.0-$61.0 billion from $67.0-$70.0 billion, and Adjusted diluted EPS guidance falls to $1.45-$1.65 from $3.25-$3.45. The cuts come mainly from Paxlovid and Comirnaty: Paxlovid revenue is reduced by about $7.0 billion, including a non-cash $4.2 billion reversal tied to the return of roughly 7.9 million EUA-labeled treatment courses, and Comirnaty revenue is reduced by about $2.0 billion on lower-than-expected vaccination rates. Pfizer also recorded a $5.5 billion non-cash charge in Q3 2023, mostly for Paxlovid inventory write-offs ($4.6 billion), with the remainder for Comirnaty. The amended U.S. government Paxlovid agreement removes a major uncertainty by setting a path to commercialization on January 1, 2024. Under the deal, the government returns unused EUA inventory in exchange for a credit that funds a patient assistance program, and Pfizer will supply 1.0 million courses to the Strategic National Stockpile. Commercial sales to privately insured patients will begin in 2024 at negotiated prices, and revenue will be recognized as product is delivered. Management says non-COVID products remain on track for 6-8% operational growth in 2023. The company also launched a multi-year enterprise-wide cost realignment program targeting at least $3.5 billion in savings ($1.0 billion in 2023, at least $2.5 billion in 2024) at one-time costs of about $3.0 billion, mostly cash. The $1.0 billion of 2023 savings partly offsets the guidance cut, and Pfizer expects to incorporate the program into 2024 guidance. Key risks for investors include continued uncertainty around COVID demand, the pace of the commercial transition, and whether the savings and restructuring costs play out as estimated.

Oct 13, 2023 10-Q

PFIZER INC Quarterly Report for Q3 Ended Jul 2, 2023

Pfizer Inc. (PFE) reported a significant decrease in revenue for the second quarter and first six months of 2023 compared to the prior year, primarily driven by lower sales of its COVID-19 products, Comirnaty and Paxlovid. Total revenues for the second quarter were $12.7 billion, down 54% year-over-year, while the six-month revenue was $31.0 billion, a 42% decrease. Excluding these COVID-19 products, Pfizer saw operational revenue growth of 5% in both periods, fueled by recently acquired products and strong performance in its Vyndaqel family. The company's strategic focus is shifting, as evidenced by the pending acquisition of Seagen, a move to bolster its oncology portfolio. Despite the top-line decline due to the expected phasing out of COVID-19 related sales, Pfizer's underlying business demonstrates resilience with growth in key non-COVID-19 products. The company is actively managing its portfolio and investing in R&D, with a significant upcoming event being the proposed acquisition of Seagen, which is expected to be financed through a combination of debt and existing cash. Investors should monitor the integration of acquired assets and the impact of ongoing patent expirations on future revenue streams.

Aug 9, 2023 8-K

PFIZER INC 8-K Report, Financial Results (Aug 1, 2023)

Pfizer reported second-quarter 2023 revenues of $12.7 billion, down 54% year over year, as COVID-19 products Paxlovid and Comirnaty collapsed from their pandemic-era peak. Excluding those two products, revenues grew 5% operationally, and management pointed to a second-half acceleration in non-COVID growth driven by a dense slate of launches. Reported diluted EPS was $0.41 (down 77%) and Adjusted diluted EPS was $0.67 (down 67%), reflecting the revenue decline, higher SI&A and R&D spending, and a sharply negative effective tax rate of (3.1)% from global tax resolutions. The company narrowed its full-year 2023 revenue guidance to $67-70 billion from $67-71 billion and cut its non-COVID operational growth expectation to 6-8% from 7-9%, citing short-term headwinds such as a restricted Talzenna label, a CDC shared-decision-making recommendation for Abrysvo, and tornado damage at its Rocky Mount, N.C. sterile injectables plant. Adjusted EPS guidance of $3.25-3.45 was maintained. Pfizer also disclosed that it completed a $31 billion debt offering to finance the pending Seagen acquisition, which it expects to close in late 2023 or early 2024, and that no share repurchases have been made in 2023. For investors, the key questions are the pace of COVID product transition to commercial markets in the second half, whether the launch cadence offsets the loss of COVID revenue, and how quickly leverage from the Seagen financing is reduced. The filing itself is a routine earnings furnishing under Item 2.02 and does not contain new material events beyond the reported results and guidance update.

Aug 1, 2023 8-K

PFIZER INC 8-K Report, Executive Changes (Jul 27, 2023)

Pfizer Inc. announced a significant restructuring of its Research and Development (R&D) organization, strategically elevating Oncology to a standalone unit. This move is directly linked to Pfizer's planned future investments in oncology, including the proposed acquisition of Seagen Inc. The new structure aims to enhance focus and agility within its cancer drug development pipeline. As part of this reorganization, Dr. Mikael Dolsten, Chief Scientific Officer and President of Pfizer R&D, will oversee consolidated early and late-stage development, while Dr. Chris Boshoff transitions to Chief Oncology Research and Development Officer. Importantly, Dr. William Pao, the former Chief Development Officer, will be leaving the company effective August 15, 2023, due to the elimination of his role. His departure is classified as an involuntary termination without cause, triggering specific severance and equity acceleration provisions as outlined in his employment agreements and company plans.

Jul 27, 2023 8-K

PFIZER INC 8-K Report, Corporate Update (May 19, 2023)

Pfizer Inc. (PFE) has announced the completion of a substantial public offering totaling $30 billion in aggregate principal amount across eight different note issuances, ranging from 2025 to 2063 maturities and carrying interest rates between 4.450% and 5.340%. These notes are fully and unconditionally guaranteed by Pfizer Inc. on a senior unsecured basis. The primary purpose of this significant debt issuance is to finance a portion of the consideration for Pfizer's proposed acquisition of Seagen Inc. An important detail for investors is the conditional nature of the debt utilization. If the Seagen acquisition does not close by a specified date (or if Pfizer decides not to pursue it), a Special Mandatory Redemption will be triggered for most of the notes (excluding the 2033 and 2053 Notes). In such an event, these redeemed notes will be repurchased at 101% of their principal amount plus accrued interest. The proceeds from the 2033 and 2053 Notes, however, would be available for general corporate purposes, potentially including existing debt obligations.

May 19, 2023 8-K

PFIZER INC 8-K Report, Corporate Update (May 15, 2023)

This 8-K filing from Pfizer Inc. (PFE) provides an update on the pending acquisition of Seagen Inc. The key information for investors is that Pfizer and Seagen have submitted their respective notification and report forms under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. This is a necessary step in the regulatory approval process for the merger. While the filing confirms the HSR submission, it does not offer any new financial data or significant strategic shifts. Investors should note that the closing of the merger remains contingent on several factors, including the expiration or termination of the HSR waiting period and potential approval from the European Commission (EC) if the merger is referred for review. The timing of these regulatory approvals will be a critical determinant of when the Seagen acquisition will be completed and when Pfizer can begin to realize the anticipated benefits of this transaction.

May 15, 2023